|
||
| The Copaxone News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| March 2005 | |||||
| June 2005 | |||||
| July 2005 | |||||
| August 2005 | |||||
| October 2005 | |||||
| November 2005 | |||||
| December 2005 | |||||
| January 2006 | |||||
| February 2006 | |||||
| May 2006 | |||||
| June 2006 | |||||
| August 2006 | |||||
| October 2006 | |||||
| November 2006 | |||||
| December 2008 | |||||
| January 2013 | |||||
| May 2013 | |||||
| June 2013 | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| November 2013 | |||||
| November 2014 | |||||
| December 2014 | |||||
| January 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| February 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Wednesday
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Labels: Aubagio, Avonex, Betaseron, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri
Friday
Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR
Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business. #2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
Read more »
Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Extavia, Gilenya, Rebif, TECFIDERA, Tysabri
85 STORIES & STUDIES HAVE BEEN POSTED IN MARCH'S NEWS SO FAR
- "It takes about 2 x as long for someone with MS to absorb and process information as someone who does not have MS: Back to School With MS? Here's How"
- Multiple Sclerosis Treatment Options: Breakdown of Associated Risks
- Study: Tysabri (Natalizumab) to fingolimod washout in patients at risk of PMLFingolimod, Tysabri
- Neil Cavuto on Feeling Moved to Tell His Viewers: ‘It’s Not Me, It’s The Multiple Sclerosis’
- Merck KGaA shores up Rebif defenses to fend off new MS rivalsRebif
- Play the MS Matching Game: brain games can help exercise your mind
- Survey showed strong uptake of the new 40-milligram, thrice-weekly version of Teva's Copaxone, estimating that about 40% of MSers will have switched to it after two yearsCopaxone
- New warning suggested for Ambien...the same sleeping pill that landed a Kennedy before a jury: says patients shouldn't drive for 8 hours after they take meds like Ambien
- $15 Million awarded to former Newark teacher with MS who says district retaliated against her
- A Glittering Rock Reunion of 14,300 Fans Becomes the Best of Get-Well Gifts for Guitarist Ronnie Lane
- Study: 2014 Multiple Sclerosis Therapeutic Update, UCSF MS Department of Neurology, San Francisco, CA
- Study: High prevalence and no latitude gradient of multiple sclerosis in Norway
- Study: Supervised exercise training has substantial benefits for MSers, yet 80% of those with MS do not meet recommended levels of moderate-to-vigorous physical activity (MVPA)
- "British Health Minister Edwin Poots witnessed first-hand how oxygen therapy can help MSers enjoy a better quality of life"
- Illinois lottery game fund multiple sclerosis research
- BREAKING NEWS! WARNING: Pfizer Issues Nationwide Recall of Antidepressant Effexor
- For Runner With M.S., No Pain While Racing, No Feeling at the Finish (New York Times)
- A MSer's story of how she & her Neuro both had problems with Anthem BlueCross getting her MS treatment refilled:10 BEST
- Doctors’ #1 Source for Healthcare Information: Wikipedia
- Merck KGaA shores up Rebif defenses to fend off new MS rivals
- Novartis, Sanofi, Biogen tout new MS drug researchAubagio, Copaxone, Gilenya, Tysabri
- My recent struggles made me realize, you only live life one time
- "Innate Immunotherapeutics delivered results from animal studies which further support its novel MIS416 therapy as a candidate to treat Secondary Progressive Multiple "Sclerosis (SPMS)
- Oregon Health & Science University today announced the creation of the OHSU Center for Embryonic Cell and Gene Therapy, led by Shoukhrat Mitalipov, Ph.D., a world-renowned leader in embryonic stem cell and gene therapy research
- Study: Neglecting data from individuals with MS who exhibit head movement during functional magnetic resonance imaging (fMRI) scanning may bias sampling away from individuals with lower cognitive ability
- Study: MiR-126: a novel route for Tysabri (natalizumab) action?Tysabri
- "Dr. Monson has developed a validated method for pre-testing people living with MS to determine if they are a carrier of a unique antibody gene that leads to the disease, thus mitigating the long-standing challenge of diagnosis"
- MS trial to explore vitamin D links
- Study: Oxygen Cost of Walking in Persons with Multiple Sclerosis: Disability Matters, but Why?
- A SAD BUT IMPORTANT LESSON FOR ALL MSers: "Inquest hears how MSer dropped match or cigarette onto her bed that engulfed her in flames and burnt down her home
- This MSer believes marijuana helped put his MS in remission: soon however, Davidson will be forced to destroy the medicine he credits with saving his life
- Biogen Idec finished 2013 on a high note, with its highly touted oral multiple sclerosis drug Tecfidera producing nearly $400 million in sales during the fourth
- Study Findings from Biogen Idec, Inc. Provide New Insights into Multiple Sclerosis
- Slightest change makes myelin come unglued: One common characteristic of diseased myelin is swelling due to MS
- OMG of the week: Doctors flee homes after declaring strike
- What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?
- How Inactivity Change MSer's Brains
- One-liners may hint at feelings about health care
- RUNNING HELPS ME MANAGE MY MS: Jeanine Parson
- I'm a mother of 3 young children and here's my horror story of my MS & the new health care law
- TAKEDA ADMITS TO IMPROPERLY MARKETING BLOCKBUSTER DRUG a AFTER DOCTOR POINTS OUT DATA IN AD DIDNT MATCH RESULTS OF CLINICAL STUDY
- Study: “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis
- Clues To Causes Of Nerve Cell Degeneration in MS Provided By Spasticity Gene Finding
- Minn. physicians ponder medical pot: Is marijuana an effective treatment for pain, illness and disease?
- Study: MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge
- Variables associated with patient activation in persons with multiple sclerosis
- What Vitamin D Dosage Do I need? How Much Sun Do I Need?
- Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?
- Express Scripts stops covering older, commonly used treatments such as Bayer's multiple sclerosis drug Betaseron on clinical, cost-effectiveness grounds
- Study: Antiviral drug Ganciclovir Inhibits Neuroinflammation in Mouse Model of MS
- Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis
- Study: Constraint-induced movement therapy increased neuroplasticity in MS patients according to MRI findings, whereas massage, yoga, and other "complementary/alternative medicine" treatments did not.
- Arshiya’s special talent: I used to jump all the way down the steps in Hodge Lee in one leap. I felt like Superman, or rather, Superwoman. That was before I got MS
- TEVA'S COPAXONE PATENT IS UP AND ITS DESPERATE TO KEEP PATIENTS & INSURERS
- DOES THIS NEW STUDY MEAN ANYTHING FOR MS PATIENTS?: "Medical Marijuana: Studies Find No Benefit for RA: Rheumatologists should not currently be recommending the use of medical marijuana to their patients for relief of chronic pain, researchers stated
- 4 Things All Doctors Need To Know About Health IT Security
- Video: THE SCANDAL THAT ROCKED THE PATIENT SAFETY MOVEMENT BREAK...
- CAN CAFFEINE HELP AN MSers MEMORY: Caffeine’s little memory jolt garners a lot of excitement
- Air Force Academy's future rests in Lt. Gen. Michelle Johnson steady hands: the institution's first female superintendent, has been tearing down barriers all her life including MS
- Senate Passes Casey MS Resolution Ahead of Multiple Sclerosis Awareness Week
- "MS doesn't define us - it's just there"
- 7 women are suing Doctor & health network for medical negligence, claiming the doctor misdiagnosed them with multiple sclerosis
- "My 1st experience as an immunologist diagnosed with MS" by Griselda Zuccarino-Catina, PH.D.
- DOCTORS BEDSIDE MANNER: written by a doctor
- Immunophenotyping Separates MS Subtypes by Neuroinflammation
- What's new in the fight against MS? USA Today
- Another big beast joins the MS Drug fray: ofatumumab phase 2 trial results
- MSnewsChanel.com.com
- Study may provide future insights into causes and mechanisms of MS
- 30% of the 16,651 people who died of an opioid overdose also had taken a benzodiazepine
- Working as a full time police officer & living with MS
- Here's 5 ways to help ease the pain of winter months
- Obamacare Hikes Cost to Patients of Specialty Drugs for MS
- The battle of a 6th grader recently diagnosed with MS
- Study: Stethoscopes carry more bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), than a physician’s hand
- Merck's Rebif is a 3rd major MS drug to be discovered in Israel: The Israeli Connection
- Kristen discovers running as way to combat her MS
- Cara Therapeutics has exciting new MS drugs in their pipeline
- Study: See One, Do One: Watching Action Boosts Brain Volume, Ability
- Study: Graph theoretical analysis indicates cognitive impairment in MS stems from neural disconnection
- We've posted 314 Studies & Stories for you so far this week
- FOR DOCTORS ONLY: 15 Smartphone Apps to Improve Your PracticeDocs Only
- WEEKEND LOL REPORT: Medical School Limiting the Number of Creepy Applicants to Cut Down on Creepy Doctors
- Video: 'Dallas Buyers Club' connects with MSers
- FOR DOCTORS ONLY: Study Companion: Mastering Clinical Concepts in MS Management
Labels: Aubagio, Betaseron, Gilenya, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri
CLICK HERE AND READ THEM PLUS OTHERS WE WILL BE POSTING!! LOTS OF EXCITING NEWS FOR MSers!!:
CLICK HERE AND READ THEM PLUS OTHERS WE WILL BE POSTING!! LOTS OF EXCITING NEWS FOR MSers!!:
www.MSnewsChannel.com
ECTRIMS: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -
ECTRIMS Congress 2013: New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
ECTRIMS Congress 2013: SLIDE SHOW: WHY GREY MATTERS...BRAIN ATROPHY IN MS: WHAT ARE ITS CONSEQUENCES?
ECTRIMS Congress 2013: Higher Vitamin D Levels Linked to Less MS Activity
ECTRIMS Congress 2013: African Americans With MS at More Visual Risk
ECTRIMS Congress 2013: Biogen covers all bases for personalised approach to MS
Halting MS to Be Focus at ECTRIMS Congress 2013
ECTRIMS Congress 2013: New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis
ECTRIMS Congress 2013: Scientists from ENDECE Neural presented preclinical data today showing that the company’s lead compound, NDC-1308, addresses one of the root causes of multiple sclerosis (MS) by significantly inducing remyelination in nerves that have been damaged by MS
ECTRIMS Congress 2013: Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
ECTRIMS Congress 2013: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -
ECTRIMS Congress 2013: Biogen Idec's new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least 4 years with no new safety problems
ECTRIMS Congress 2013: COPAXONE (Glatiramer acetate) 20 mg daily associated with stable disease activity over the course of the twenty-year study presented at the 29th ECTRIMS congress
ECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates
ECTRIMS Congress 2013: GILENYA REDUCES MS RELAPSE RATES COMPARED TO INTERFERONS OR GLATIRAMER ACETATE
ECTRIMS Congress 2013: NOVARTIS, SANOFI AND BIOGEN TOUT NEW MS DRUG RESEARCH
ECTRIMS Congress 2013: "BRAIN ATROPHY CAN PRECEDE MS SYMPTOM"
ECTRIMS Congress 2013: "EARLY, STEADY MS TREATMENT CUTS PROGRESSION RISK" (Day 1 ECTRIMS News)
ECTRIMS Congress 2013: Vitamin D for All to Prevent MS? Vitamin D for all MSers?
www.MSnewsChannel.com
ECTRIMS: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -
ECTRIMS Congress 2013: New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
ECTRIMS Congress 2013: SLIDE SHOW: WHY GREY MATTERS...BRAIN ATROPHY IN MS: WHAT ARE ITS CONSEQUENCES?
ECTRIMS Congress 2013: Higher Vitamin D Levels Linked to Less MS Activity
ECTRIMS Congress 2013: African Americans With MS at More Visual Risk
ECTRIMS Congress 2013: Biogen covers all bases for personalised approach to MS
Halting MS to Be Focus at ECTRIMS Congress 2013
ECTRIMS Congress 2013: New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis
ECTRIMS Congress 2013: Scientists from ENDECE Neural presented preclinical data today showing that the company’s lead compound, NDC-1308, addresses one of the root causes of multiple sclerosis (MS) by significantly inducing remyelination in nerves that have been damaged by MS
ECTRIMS Congress 2013: Aubagio(R) Significantly Reduced Risk of New Clinical Relapse or MRI Lesion in Multiple Sclerosis Study
ECTRIMS Congress 2013: TYSABRI Use Beyond Two Years Continued to Reduce Disability Progression and Maintained Very Low Relapse Rates -
ECTRIMS Congress 2013: Biogen Idec's new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least 4 years with no new safety problems
ECTRIMS Congress 2013: COPAXONE (Glatiramer acetate) 20 mg daily associated with stable disease activity over the course of the twenty-year study presented at the 29th ECTRIMS congress
ECTRIMS Congress 2013: Oral MS drug Gilenya® shows up to 71% reduction in annualised relapse rates
ECTRIMS Congress 2013: GILENYA REDUCES MS RELAPSE RATES COMPARED TO INTERFERONS OR GLATIRAMER ACETATE
ECTRIMS Congress 2013: NOVARTIS, SANOFI AND BIOGEN TOUT NEW MS DRUG RESEARCH
ECTRIMS Congress 2013: "BRAIN ATROPHY CAN PRECEDE MS SYMPTOM"
ECTRIMS Congress 2013: "EARLY, STEADY MS TREATMENT CUTS PROGRESSION RISK" (Day 1 ECTRIMS News)
ECTRIMS Congress 2013: Vitamin D for All to Prevent MS? Vitamin D for all MSers?
Labels: Aubagio, ECTRIMS CONGRESS 2013, Gilenya, TECFIDERA, Tysabri, Vitamin D
VIDEO: TEVA'S DISASTEROUS DROP IN STOCK PRICE:
"Ive been on Avonex & Rebif: so 3 times a week I lost a full day afterward due to interferon drugs"
Multiple sclerosis has not been an easy road for me Stan. Since being diagnosed with MS in 2004, I have been on two different interferon drugs (Avonex and Rebif). Both drugs had a great deal of side effects and I would often suffer for at least 24 hours each time I injected the medication. Can you imagine injecting a drug 3 times a week when you literally loose a full day afterward?
During a year and a half of my interferon routine, I was also put on the chemotherapy drug Cytoxan due to the rapid progression of my MS. Now, I not only dealt with the interferon reactions, but I suddenly was dealing with the serve side effects of the chemotherapy.
When I could no longer take the idea of being on the interferons and chemotherapy, I begged to be put on something else. My doctor finally settled on the drug Tysabri. Things seemed to be a bit better. I was on Tysabri for about 23 months when I developed a fungal lung infection called Valley Fever. It was determined that it was best for me to stop the Tysabri and go on the drug Copaxone.
Copaxone injections worked well for me for about for a year and a half. Then suddenly they stopped working for me and I had two new lesions hit me last fall. One of the lesions was at C2 on my spine. This one caused me to loose function and feeling in all of my right side with a lot of my left starting to follow. Needless to say, this was quite frightening. It was a sad reminder that at any point in my life, I may suddenly become paralyzed or blind because of this disease.
We were now at a crossroads. The Copaxone was no longer slowing the progression of my MS and we were still anxiously waiting for the new oral drugs that the drug companies had been promising for years. Finally, in June of this year, my doctor put me on the new oral drug Tecfidera! Just being off the daily shots of Copaxone was exciting enough, but not having too many side effects that interrupted my daily routine is a huge plus.
Tecfidera (Dimethyl fumarate) was approved by the FDA on March 27, 2013. It had previously been used, under a different name, to treat things like psoriasis, necrobiosis lipoidica, granuloma annulare, and sarcoidosis in Europe since 1994. Tecfidera is currently being used to treat relapsing remitting forms of MS. It has been shown to reduce relapses and slow the progression of physical disability. It is an oral drug that is taken twice daily. Tecfidera does have the potential of decreasing a patients white blood cell counts. The most common side effects of Tecfidera are stomach upset and flushing.
My experience on the Tecfidera has been very positive so far. I did experience some minimal flushing the first two weeks of taking the medication, but this has since resolved. My only other side effects have been with the stomach upset. In the beginning, I experienced minimal nausea and diarrhea. I discovered that if I took Pepcid with each dose of the Tecfidera, the nausea was no longer an issue. The diarrhea has also calmed down and I now only get it on occasion and nothing that is too terrible to deal with. Overall, I only experienced most of these side effects the first month on the medication.
How do I feel now that I have been on the Tecfidera for four months? Great! I still cannot run or walk a marathon, but I do have a bit more energy. Naps were a must for me every day. I can now go without a nap on most days and I sleep better at night. So far my MRI’s look good and I have no new lesion activity. Only time will tell if this new wonder drug will continue to slow down my progression of this disease. MS is funny. It has no rhyme or reason really. It just attacks when it feels the need and never really gives you any warning. A person with MS must learn to take life a day at a time. You can make plans but there is always that chance that those plans must change. God has taught me to slow down and appreciate each and every day. Hopefully with drugs like Tecfidera, I and others with MS, will have many good days, months and years ahead.
Labels: Avonex, Copaxone, Rebif, TECFIDERA, Tysabri
15 STUDIES IN FRIDAY'S NEWS
15 STUDIES IN FRIDAY'S NEWS
PLUS: 471 new Studies we posted from 11/1 to Thursday 12/5 Start at the Bottom!
Read more »
PLUS: 471 new Studies we posted from 11/1 to Thursday 12/5 Start at the Bottom!
471 STUDIES FROM 11/1 to Thursday 12/5 are below:
Labels: Avonex, Betaseron, Extavia, Gilenya, Novantrone, Rebif, TECFIDERA, Tysabri
Data Show Declining Use of Injectables as Oral Multiple Sclerosis Therapies Gain Traction
"Researchers don’t know why some multiple sclerosis therapies work"
Thursday
"RESEARCHERS DON'T KNOW WHY SOME MS TREATMENTS WORK"
Researchers don’t know why some multiple sclerosis therapies work
Can new versions of Copaxone, Avonex drive market share retention?
HOW MS MEDICATIONS DIFFER FROM EACH OTHER
Read more »
Labels: Aubagio, Avonex, Betaseron, Extavia, Gilenya, Novantrone, Rebif, TECFIDERA, Tysabri
Tecfidera Captures the Largest U.S. Neurologist-Reported Patient Share Among Oral Disease-Modifying Multiple Sclerosis Therapies Ten Months Post-Launch
Tecfidera Is Off to a Quick Start
Sunday
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Labels: Aubagio, Avonex, Betaseron, Extavia, Gilenya, Lemtrada, Rebif, Rituxan-Rituximab, TECFIDERA, Tysabri
"COPAXONE IS HEADED OFF A CLIFF: It's painfully clear that generic competitors such as Mylan, Momenta, and Novartis' Sandoz unit will roll out generic Copaxone on time"
Oral MS drugs could exacerbate Copaxone's decline. Meanwhile, the three main oral MS drugs -- Novartis' Gilenya, Biogen's Tecfidera, and Sanofi's Aubagio -- could all bury Copaxone in its key U.S. market. Click to read how fast these treatments have been selling, despite their limited time on the market.
Labels: Aubagio, Gilenya, TECFIDERA
15 STUDIES IN FRIDAY'S NEWS
PLUS: 1590 new Studies we posted from 11/1 to Thursday 2/12 Start at the Bottom!
The NBSS, developed specifically to assess the symptoms and consequences associated with neurogenic bladder dysfunction, has appropriate psychometric properties. Depending on the measurement need, individual domains may be selected, or it can be used as a comprehensive score.
The fraction of intrathecally-produced VZV-specific IgG of the total intrathecally produced IgG discriminates between patients with VZV reactivation and MS. Our results provide further evidence that intrathecally-produced VZV antibodies are part of the polyspecific immune response in patients with MS.
In addition to autoantigens implicated in thyroid autoimmunity, fibrocytes and derivative fibroblasts express multiple autoantigens associated with T1DM. This expression results from active gene promoters and abundant steady-state mRNA encoding ICA69 and IA-2. These latest findings demonstrate that fibrocytes express antigens relevant to multiple forms of endocrine autoimmunity. They suggest the potential for these cells playing a direct role in immune reactivity directed at the thyroid and pancreatic islets.
MMPs can also enhance the cleavage of myelin basic protein (MBP) and the demyelination process. Regarding the growing data on the roles of MMPs and their tissue inhibitors (TIMPs) in the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.
In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
Read Study Pubmed.gov
Labels: 500 BEST PML STORIES & STUDIES, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, PML (Progressive Multifocal Leukoencephalopathy), Rebif, sativex, TECFIDERA, Tysabri
15 STUDIES IN THURSDAY'S NEWS
PLUS: 1575 new Studies we posted from 11/1 to Wednesday 2/12 Start at the Bottom!
In patients with SSc, serum levels of ICAM-1 and P-selectin may serve as prognostic indicators of respiratory dysfunction and physical disability, respectively. Further longitudinal studies of larger populations are needed to confirm these findings.
Seizures can occur at any stage during the course of MS, but it is more common during the early stages.
In a real-world setting, patients with MS who switched from IFNs to fingolimod were significantly less likely to experience relapses than those who switched to GA.
In the NARCOMS cohort, functional health literacy is high. However, lower levels of health literacy are associated with adverse health behaviors and greater health care utilization.
Read Study at Pubmed.gov
In the pathogenesis of MS, this review discusses the role of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment of MS.
Read Study at Pubmed.gov
Read more »
Labels: 500 BEST PML STORIES & STUDIES, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, PML (Progressive Multifocal Leukoencephalopathy), Rebif, sativex, TECFIDERA, Tysabri
15 STUDIES IN WEDNESDAY'S NEWS
PLUS: 1560 new Studies we posted from 11/1 to Tuesday 2/11 Start at the Bottom!Seminal data regarding its use in MS, the known mechanism(s) of action, and contemporary studies focusing on efficacy and safety data will be reviewed. The role of chemotherapeutic agents in the management of MS and implications for therapeutic intervention are also discussed.
Read Study at Pubmed.gov
The best current evidence for the efficacy of glucocorticoid treatment in MS, by far, comes from the optic neuritis treatment trial, which used high-dose intravenous methylprednisolone for the first 3 days followed by an 11-day course of low-dose oral prednisone.
Read Study at Pubmed.gov
It is hoped that, through an understanding of the earliest aspects of the MS disease process, critical insights will be gained about the genesis of MS.
Read Study at Pubmed.gov
Major technical improvements in MRI hardware and pulse sequence design allow more specific and potentially more sensitive treatment metrics required for targeting outcomes most relevant to neuronal degeneration, remyelination and repair.
Read Study at Pubmed.gov
This chapter reviews the current evidence, taken from both clinical and paraclinical sources, as it relates to establishing this prognosis and provides insight to where, in the future, we need to look.
Read Study at Pubmed.gov
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Novantrone, Rebif, sativex, TECFIDERA, Tysabri